TY - JOUR AU - Touraine, P. AU - Martini, J. -. F. AU - Zafrani, B. AU - Durand, J. -. C. AU - Labaille, F. AU - Malet, C. AU - Nicolas, A. AU - Trivin, C. AU - Postel-Vinay, M. -. C. AU - Kuttenn, F. PY - 1998 DA - 1998// TI - Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues JO - J Clin Endocrinol Metab VL - 83 UR - https://doi.org/10.1210/jcem.83.2.4564 DO - 10.1210/jcem.83.2.4564 ID - Touraine1998 ER - TY - JOUR AU - Reynolds, C. AU - Montone, K. T. AU - Powell, C. M. AU - Tomaszewski, J. E. AU - Clevenger, C. V. PY - 1997 DA - 1997// TI - Expression of prolactin and its receptor in human breast carcinoma JO - Endocrinology VL - 138 UR - https://doi.org/10.1210/endo.138.12.5605 DO - 10.1210/endo.138.12.5605 ID - Reynolds1997 ER - TY - JOUR AU - Gill, s. S. AU - Peston, D. AU - Vonderhaar, B. AU - Shousha, S. PY - 2001 DA - 2001// TI - Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study JO - J Clin Pathol VL - 54 UR - https://doi.org/10.1136/jcp.54.12.956 DO - 10.1136/jcp.54.12.956 ID - Gill2001 ER - TY - JOUR AU - Zhu, J. PY - 2012 DA - 2012// TI - Mammalian cell protein expression for biopharmaceutical production JO - Biotechnol Adv VL - 30 UR - https://doi.org/10.1016/j.biotechadv.2011.08.022 DO - 10.1016/j.biotechadv.2011.08.022 ID - Zhu2012 ER - TY - JOUR AU - Damiano, J. S. AU - Rendahl, K. G. AU - Karim, C. AU - Embry, M. G. AU - Ghoddusi, M. AU - Holash, J. AU - Fanidi, A. AU - Abrams, T. J. AU - Abraham, J. A. PY - 2013 DA - 2013// TI - Neutralization of prolactin receptor function by monoclonal antibody lfa102, a novel potential therapeutic for the treatment of breast cancer JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-12-0886 DO - 10.1158/1535-7163.MCT-12-0886 ID - Damiano2013 ER - TY - JOUR AU - Agarwal, N. AU - Machiels, J. -. P. AU - Suárez, C. AU - Lewis, N. AU - Higgins, M. AU - Wisinski, K. AU - Awada, A. AU - Maur, M. AU - Stein, M. AU - Hwang, A. PY - 2016 DA - 2016// TI - Phase i study of the prolactin receptor antagonist lfa102 in metastatic breast and castration-resistant prostate cancer JO - Oncologist VL - 21 UR - https://doi.org/10.1634/theoncologist.2015-0502 DO - 10.1634/theoncologist.2015-0502 ID - Agarwal2016 ER - TY - JOUR AU - Kelly, M. P. AU - Hickey, C. AU - Makonnen, S. AU - Coetzee, S. AU - Jalal, S. AU - Wang, Y. AU - Delfino, F. AU - Shan, J. AU - Potocky, T. B. AU - Chatterjee, I. PY - 2017 DA - 2017// TI - Preclinical activity of the novel anti-prolactin receptor (prlr) antibody–drug conjugate regn2878-dm1 in prlr-positive breast cancers JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-16-0839 DO - 10.1158/1535-7163.MCT-16-0839 ID - Kelly2017 ER - TY - JOUR AU - Andreev, J. AU - Thambi, N. AU - Bay, A. E. P. AU - Delfino, F. AU - Martin, J. AU - Kelly, M. P. AU - Kirshner, J. R. AU - Rafique, A. AU - Kunz, A. AU - Nittoli, T. PY - 2017 DA - 2017// TI - Bispecific antibodies and antibody–drug conjugates (adcs) bridging her2 and prolactin receptor improve efficacy of her2 adcs JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-16-0658 DO - 10.1158/1535-7163.MCT-16-0658 ID - Andreev2017 ER - TY - JOUR AU - O’Sullivan, C. C. AU - Bates, S. E. PY - 2016 DA - 2016// TI - Targeting prolactin receptor (prlr) signaling in prlr-positive breast and prostate cancer JO - Oncologist VL - 21 UR - https://doi.org/10.1634/theoncologist.2016-0108 DO - 10.1634/theoncologist.2016-0108 ID - O’Sullivan2016 ER - TY - JOUR AU - Iwai, Y. AU - Hamanishi, J. AU - Chamoto, K. AU - Honjo, T. PY - 2017 DA - 2017// TI - Cancer immunotherapies targeting the pd-1 signaling pathway JO - J Biomed Sci VL - 24 UR - https://doi.org/10.1186/s12929-017-0329-9 DO - 10.1186/s12929-017-0329-9 ID - Iwai2017 ER - TY - JOUR AU - Leshem, Y. AU - O’Brien, J. AU - Liu, X. AU - Bera, T. K. AU - Terabe, M. AU - Berzofsky, J. A. AU - Bossenmaier, B. AU - Niederfellner, G. AU - Tai, C. -. H. AU - Reiter, Y. PY - 2017 DA - 2017// TI - Combining local immunotoxins targeting mesothelin with ctla-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0330 DO - 10.1158/2326-6066.CIR-16-0330 ID - Leshem2017 ER - TY - JOUR AU - Littman, D. AU - Hexner, E. PY - 2017 DA - 2017// TI - Cancer immunotherapy with chimeric antigen receptor (car) t cells JO - J Onco-Nephrol VL - 1 UR - https://doi.org/10.5301/jo-n.5000035 DO - 10.5301/jo-n.5000035 ID - Littman2017 ER - TY - JOUR AU - Bommareddy, P. K. AU - Shettigar, M. AU - Kaufman, H. L. PY - 2018 DA - 2018// TI - Integrating oncolytic viruses in combination cancer immunotherapy JO - Nat Rev Immunol VL - 18 UR - https://doi.org/10.1038/s41577-018-0014-6 DO - 10.1038/s41577-018-0014-6 ID - Bommareddy2018 ER - TY - JOUR AU - Huehls, A. M. AU - Coupet, T. A. AU - Sentman, C. L. PY - 2015 DA - 2015// TI - Bispecific t-cell engagers for cancer immunotherapy JO - Immunol Cell Biol VL - 93 UR - https://doi.org/10.1038/icb.2014.93 DO - 10.1038/icb.2014.93 ID - Huehls2015 ER - TY - CHAP AU - Bhandaru, M. AU - Rotte, A. PY - 2019 DA - 2019// TI - Monoclonal antibodies for the treatment of melanoma: present and future strategies BT - Human Monoclonal Antibodies PB - Springer CY - New York ID - Bhandaru2019 ER - TY - JOUR AU - Marhelava, K. AU - Pilch, Z. AU - Bajor, M. AU - Graczyk-Jarzynka, A. AU - Zagozdzon, R. PY - 2019 DA - 2019// TI - Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer JO - Cancers VL - 11 UR - https://doi.org/10.3390/cancers11111756 DO - 10.3390/cancers11111756 ID - Marhelava2019 ER - TY - JOUR AU - Wang, X. AU - Guo, G. AU - Guan, H. AU - Yu, Y. AU - Lu, J. AU - Yu, J. PY - 2019 DA - 2019// TI - Challenges and potential of pd-1/pd-l1 checkpoint blockade immunotherapy for glioblastoma JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-019-1085-3 DO - 10.1186/s13046-019-1085-3 ID - Wang2019 ER - TY - JOUR AU - Jiang, C. AU - Cao, S. AU - Li, N. AU - Jiang, L. AU - Sun, T. PY - 2019 DA - 2019// TI - Pd-1 and pd-l1 correlated gene expression profiles and their association with clinical outcomes of breast cancer JO - Cancer Cell Int VL - 19 UR - https://doi.org/10.1186/s12935-019-0955-2 DO - 10.1186/s12935-019-0955-2 ID - Jiang2019 ER - TY - JOUR AU - Kantarjian, H. AU - Jabbour, E. AU - Topp, M. S. PY - 2017 DA - 2017// TI - Blinatumomab for acute lymphoblastic leukemia JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMc1704012 DO - 10.1056/NEJMc1704012 ID - Kantarjian2017 ER - TY - JOUR AU - Seimetz, D. PY - 2011 DA - 2011// TI - Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab®) JO - J Cancer VL - 2 UR - https://doi.org/10.7150/jca.2.309 DO - 10.7150/jca.2.309 ID - Seimetz2011 ER - TY - STD TI - Tabernero J, Melero I, Ros W, Argiles G, Marabelle A, Rodriguez-Ruiz ME, Albanell J, Calvo E, Moreno V, Cleary JM, et al.Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). Am Soc Clin Oncol. 2017. ID - ref21 ER - TY - STD TI - Dillon P, Rathore R, Thakur A, Colvin G, Kouttab N, Lum L. Abstract p1-08-05: A phase i trial of chemotherapy followed by infusions of activated t cells armed with anti-cd3 and anti-her2 bispecific antibody for stage iii, her2+ or her2-breast cancer. 2018. ID - ref22 ER - TY - JOUR AU - Gedeon, P. C. AU - Schaller, T. H. AU - Chitneni, S. K. AU - Choi, B. D. AU - Kuan, C. -. T. AU - Suryadevara, C. M. AU - Snyder, D. J. AU - Schmittling, R. J. AU - Szafranski, S. E. AU - Cui, X. PY - 2018 DA - 2018// TI - A rationally designed fully human egfrviii: Cd3-targeted bispecific antibody redirects human t cells to treat patient-derived intracerebral malignant glioma JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-0126 DO - 10.1158/1078-0432.CCR-17-0126 ID - Gedeon2018 ER - TY - STD TI - Lum LG, Choi M, Le TM, Thakur A, Deol A, Ballen KK, Volodin L, Kindwall-Keller TL, Liu Q, Dyson G, et al.Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody. Am Soc Clin Oncol. 2018. ID - ref24 ER - TY - JOUR AU - Sun, L. L. AU - Ellerman, D. AU - Mathieu, M. AU - Hristopoulos, M. AU - Chen, X. AU - Li, Y. AU - Yan, X. AU - Clark, R. AU - Reyes, A. AU - Stefanich, E. PY - 2015 DA - 2015// TI - Anti-cd20/cd3 t cell–dependent bispecific antibody for the treatment of b cell malignancies JO - Sci Trans Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aaa4802 DO - 10.1126/scitranslmed.aaa4802 ID - Sun2015 ER - TY - JOUR AU - Beck, A. AU - Wurch, T. AU - Bailly, C. AU - Corvaia, N. PY - 2010 DA - 2010// TI - Strategies and challenges for the next generation of therapeutic antibodies JO - Nat Rev Immunol VL - 10 UR - https://doi.org/10.1038/nri2747 DO - 10.1038/nri2747 ID - Beck2010 ER - TY - JOUR AU - Han, L. AU - Chen, J. AU - Ding, K. AU - Zong, H. AU - Xie, Y. AU - Jiang, H. AU - Zhang, B. AU - Lu, H. AU - Yin, W. AU - Gilly, J. PY - 2017 DA - 2017// TI - Efficient generation of bispecific igg antibodies by split intein mediated protein trans-splicing system JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-08641-3 DO - 10.1038/s41598-017-08641-3 ID - Han2017 ER - TY - JOUR AU - Han, L. AU - Zong, H. AU - Zhou, Y. AU - Pan, Z. AU - Chen, J. AU - Ding, K. AU - Xie, Y. AU - Jiang, H. AU - Zhang, B. AU - Lu, H. PY - 2019 DA - 2019// TI - Naturally split intein npu dnae mediated rapid generation of bispecific igg antibodies JO - Methods VL - 154 UR - https://doi.org/10.1016/j.ymeth.2018.10.001 DO - 10.1016/j.ymeth.2018.10.001 ID - Han2019 ER - TY - JOUR AU - Ding, K. AU - Han, L. AU - Zong, H. AU - Chen, J. AU - Zhang, B. AU - Zhu, J. PY - 2017 DA - 2017// TI - Production process reproducibility and product quality consistency of transient gene expression in hek293 cells with anti-pd1 antibody as the model protein JO - Appl Microbiol Biotechnol VL - 101 UR - https://doi.org/10.1007/s00253-016-7973-y DO - 10.1007/s00253-016-7973-y ID - Ding2017 ER - TY - JOUR AU - Ingberg, E. AU - Theodorsson, A. AU - Theodorsson, E. AU - Strom, J. PY - 2012 DA - 2012// TI - Methods for long-term 17 β-estradiol administration to mice JO - Gen Comp Endocrinol VL - 175 UR - https://doi.org/10.1016/j.ygcen.2011.11.014 DO - 10.1016/j.ygcen.2011.11.014 ID - Ingberg2012 ER - TY - JOUR AU - Sarkar, D. AU - Su, Z. -. z. AU - Vozhilla, N. AU - Park, E. S. AU - Gupta, P. AU - Fisher, P. B. PY - 2005 DA - 2005// TI - Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice JO - Proc Natl Acad Sci VL - 102 UR - https://doi.org/10.1073/pnas.0506837102 DO - 10.1073/pnas.0506837102 ID - Sarkar2005 ER - TY - JOUR AU - Peirce, S. AU - Chen, W. AU - Chen, W. PY - 2001 DA - 2001// TI - Quantification of prolactin receptor mrna in multiple human tissues and cancer cell lines by real time rt-pcr JO - J Endocrinol VL - 171 UR - https://doi.org/10.1677/joe.0.171r001 DO - 10.1677/joe.0.171r001 ID - Peirce2001 ER - TY - JOUR AU - Klebanoff, C. A. AU - Gattinoni, L. AU - Restifo, N. P. PY - 2006 DA - 2006// TI - Cd8+ t-cell memory in tumor immunology and immunotherapy JO - Immunol Rev VL - 211 UR - https://doi.org/10.1111/j.0105-2896.2006.00391.x DO - 10.1111/j.0105-2896.2006.00391.x ID - Klebanoff2006 ER - TY - JOUR AU - Smyth, M. J. AU - Cretney, E. AU - Kershaw, M. H. AU - Hayakawa, Y. PY - 2004 DA - 2004// TI - Cytokines in cancer immunity and immunotherapy JO - Immunol Rev VL - 202 UR - https://doi.org/10.1111/j.0105-2896.2004.00199.x DO - 10.1111/j.0105-2896.2004.00199.x ID - Smyth2004 ER - TY - STD TI - Adams S, Loi S, Toppmeyer D, Cescon D, De Laurentiis M, Nanda R, Winer E, Mukai H, Tamura K, Armstrong AC, et al.Keynote-086 cohort b: pembrolizumab monotherapy for pd-l1–positive, previously untreated, metastatic triple-negative breast cancer (mtnbc). 2018. ID - ref35 ER - TY - JOUR AU - Ghebeh, H. AU - Mohammed, S. AU - Al-Omair, A. AU - Qattant, A. AU - Lehe, C. AU - Al-Qudaihi, G. AU - Elkum, N. AU - Alshabanah, M. AU - Amer, S. B. AU - Tulbah, A. PY - 2006 DA - 2006// TI - The b7-h1 (pd-l1) t lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors JO - Neoplasia VL - 8 UR - https://doi.org/10.1593/neo.05733 DO - 10.1593/neo.05733 ID - Ghebeh2006 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2019 DA - 2019// TI - Cancer statistics, 2019 JO - CA Cancer J Clin VL - 69 UR - https://doi.org/10.3322/caac.21551 DO - 10.3322/caac.21551 ID - Siegel2019 ER - TY - JOUR AU - Goffin, V. PY - 2017 DA - 2017// TI - Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge JO - Pharmacol Ther VL - 179 UR - https://doi.org/10.1016/j.pharmthera.2017.05.009 DO - 10.1016/j.pharmthera.2017.05.009 ID - Goffin2017 ER - TY - STD TI - Van ZI, Molthoff CF, Roos JC, Verheijen RH, Van HA, Buist MR, Prinssen HM, Den HW, Kenemans P. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody mov18: i.v. vs. i.p. 2015; 92(1):106–14. ID - ref39 ER - TY - JOUR AU - Shultz, L. D. AU - Schweitzer, P. A. AU - Christianson, S. W. AU - Gott, B. AU - Schweitzer, I. B. AU - Tennent, B. AU - McKenna, S. AU - Mobraaten, L. AU - Rajan, T. AU - Greiner, D. L. PY - 1995 DA - 1995// TI - Multiple defects in innate and adaptive immunologic function in nod/ltsz-scid mice JO - J Immunol VL - 154 ID - Shultz1995 ER - TY - STD TI - McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, et al.Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. 2014. ID - ref41 ER - TY - JOUR AU - Cardoso, F. AU - Costa, A. AU - Senkus, E. AU - Aapro, M. AU - André, F. AU - Barrios, C. AU - Bergh, J. AU - Bhattacharyya, G. AU - Biganzoli, L. AU - Cardoso, M. PY - 2017 DA - 2017// TI - 3rd eso–esmo international consensus guidelines for advanced breast cancer (abc 3) JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdw544 DO - 10.1093/annonc/mdw544 ID - Cardoso2017 ER - TY - JOUR AU - Butte, M. J. AU - Keir, M. E. AU - Phamduy, T. B. AU - Sharpe, A. H. AU - Freeman, G. J. PY - 2007 DA - 2007// TI - Programmed death-1 ligand 1 interacts specifically with the b7-1 costimulatory molecule to inhibit t cell responses JO - Immunity VL - 27 UR - https://doi.org/10.1016/j.immuni.2007.05.016 DO - 10.1016/j.immuni.2007.05.016 ID - Butte2007 ER - TY - JOUR AU - Yang, Q. AU - Saenz, S. A. AU - Zlotoff, D. A. AU - Artis, D. AU - Bhandoola, A. PY - 2011 DA - 2011// TI - Cutting edge: Natural helper cells derive from lymphoid progenitors JO - J Immunol VL - 187 UR - https://doi.org/10.4049/jimmunol.1102039 DO - 10.4049/jimmunol.1102039 ID - Yang2011 ER - TY - JOUR AU - Beckers, R. K. AU - Selinger, C. I. AU - Vilain, R. AU - Madore, J. AU - Wilmott, J. S. AU - Harvey, K. AU - Holliday, A. AU - Cooper, C. L. AU - Robbins, E. AU - Gillett, D. PY - 2016 DA - 2016// TI - Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome JO - Histopathology VL - 69 UR - https://doi.org/10.1111/his.12904 DO - 10.1111/his.12904 ID - Beckers2016 ER - TY - JOUR AU - Mittendorf, E. A. AU - Philips, A. V. AU - Meric-Bernstam, F. AU - Qiao, N. AU - Wu, Y. AU - Harrington, S. AU - Su, X. AU - Wang, Y. AU - Gonzalez-Angulo, A. M. AU - Akcakanat, A. PY - 2014 DA - 2014// TI - Pd-l1 expression in triple-negative breast cancer JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0127 DO - 10.1158/2326-6066.CIR-13-0127 ID - Mittendorf2014 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. -. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. AU - Sosman, J. A. AU - McDermott, D. F. AU - Powderly, J. D. AU - Gettinger, S. N. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-pd-l1 antibody mpdl3280a in cancer patients JO - Nature VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Hamm, C. A. AU - Moran, D. AU - Rao, K. AU - Trusk, P. B. AU - Pry, K. AU - Sausen, M. AU - Jones, S. AU - Velculescu, V. E. AU - Cristofanilli, M. AU - Bacus, S. PY - 2016 DA - 2016// TI - Genomic and immunological tumor profiling identifies targetable pathways and extensive cd8+/pdl1+ immune infiltration in inflammatory breast cancer tumors JO - Mol Cancer Ther VL - 15 UR - https://doi.org/10.1158/1535-7163.MCT-15-0353 DO - 10.1158/1535-7163.MCT-15-0353 ID - Hamm2016 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. AU - Robert, L. AU - Chmielowski, B. AU - Spasic, M. AU - Henry, G. AU - Ciobanu, V. PY - 2014 DA - 2014// TI - Pd-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER -